DIAGNOS Secures Health Canada Medical Device License for AI-Driven CARA System, Advancing Entry into Canadian Optometry Market

Health Canada Approval Paves Way for Full Commercial Launch in Canada

DIAGNOS confirmed that Health Canada issued a medical device licence for the CARA System on July 23, 2026, authorizing the company to commercialize the technology within the Canadian market. This approval allows DIAGNOS to fully serve IRIS Le Groupe Visuel and execute its commercial strategy targeting Canadian optometrists. The CARA System is recognized as one of the first Canadian AI-driven retinal image analysis platforms specifically developed for optometry to receive a Class II medical device licence from Health Canada.

This regulatory clearance culminates over a decade of DIAGNOS’s research and development in AI for retinal image analysis, conducted in partnership with clinicians and healthcare organizations globally. The company’s mission, as stated, focuses on preventing avoidable blindness through innovative diagnostic technologies.

Advanced Technology and Clinical Features of CARA System

The CARA System incorporates multiple AI-assisted analytical modules designed to streamline clinical workflows under eye care professionals’ guidance. These include CARA-AMDdetect for age-related macular degeneration detection, CARA-DR for diabetic retinopathy detection, CARA-MVA for retinal microvasculature analysis, CARA-Enhancement for advanced retinal image optimization, and CARA-CWS, a clinician workspace for annotations.

By combining image enhancement, explainable AI outputs, fundus indicators, and retinal vascular analysis, the CARA System aids clinicians in extracting clinically relevant data from each fundus photograph while ensuring optometrists maintain full control over clinical decisions. Fundus photography is already widely integrated into clinical optometry settings across independent practices and large eye care networks. CARA System leverages advanced image optimization and explainable AI to analyze every pixel of fundus images, providing objective insights into retinal conditions that may not be immediately visible.

Significance for Quebec’s Medical Technology Innovation Ecosystem

Philippe Couillard, President of DIAGNOS’s Board of Directors, described the Health Canada authorization as a landmark achievement for both DIAGNOS and Quebec’s innovation ecosystem. He emphasized that developing AI for regulated medical devices demands scientific excellence, clinical rigor, and perseverance. Couillard highlighted Quebec companies’ capabilities to design world-class medical technologies that meet stringent global regulatory standards and succeed internationally.

This regulatory approval highlights DIAGNOS’s commitment to developing diagnostically advanced solutions that comply with rigorous international standards while addressing critical healthcare needs. The technology is specifically designed to fit clinical workflows familiar to Canadian optometrists, indicating a tailored approach to regional market and professional practice requirements.

Regulatory Compliance and Medical Device Classification Details

DIAGNOS noted that the CARA System is inherently a medical device requiring formal local regulatory authorization before commercialization in most markets. Regulatory compliance ensures public safety, and the company aims to obtain marketing authorizations from Saudi Arabia’s Food & Drug Authority (SFDA) and the U.S. Food and Drug Administration (FDA).

The CARA System received Health Canada approval as a Class II medical device, reflecting both its functionality and the regulatory framework’s assessment of risk and clinical benefit. Medical device classifications vary by jurisdiction, determining the level of regulatory oversight and pre-market review necessary for legal marketing.

Saudi Arabia Regulatory Submission and Progress

DIAGNOS formally submitted the CARA System for marketing approval to Saudi Arabia’s SFDA, as disclosed in the company’s management discussion and analysis (MD&A) dated June 11, 2026. Since submission, the company has responded to additional information requests from the SFDA. No timeline for a regulatory decision in Saudi Arabia was provided.

This regulatory pursuit reflects DIAGNOS’s strategy to expand internationally beyond Canada. The Middle Eastern market is significant for healthcare technology adoption, especially in countries enhancing healthcare infrastructure and investing in diagnostic innovation.

U.S. FDA Regulatory Strategy and Timeline

A prior version of CARA, functioning as a medical image processing and management system, remains authorized for commercialization in the U.S. With support from a U.S.-based regulatory consultant, DIAGNOS aims to file the CARA System marketing application with the FDA before the end of September 2026. This is a target, not a confirmed submission date.

The distinction between the previously authorized CARA system and the new CARA System reflects technological evolution and differing regulatory pathways. The FDA approval process is among the world’s most stringent, and DIAGNOS’s engagement of specialized consultants underscores the complexity of meeting U.S. requirements.

Leadership Insights and Strategic Vision

André Larente, President and CEO of DIAGNOS, stated that the company has collaborated with clinicians worldwide for over a decade on AI for retinal image analysis, driven by a mission to prevent avoidable blindness. He described the Health Canada authorization as a major milestone and reaffirmed the company’s commitment to this goal.

Yves-Stéphane Couture, COO of DIAGNOS, expressed enthusiasm about offering the CARA System to Canadian optometrists, highlighting that the technology unlocks the full clinical value of fundus images through explainable AI while ensuring clinicians remain central to all clinical decisions. This underscores the company’s view of the technology as a tool to enhance, not replace, professional judgment.

Market Context and Integration into Clinical Practice

Fundus photography is routinely integrated into Canadian optometry practices, from independent offices to large eye care networks, providing existing infrastructure and workflows for CARA System integration. Many optometrists already have fundus imaging equipment, so adoption primarily involves software and analytical capabilities rather than new hardware.

The focus on detecting retinal diseases such as age-related macular degeneration and diabetic retinopathy targets prevalent conditions with significant public health impact. Early detection and management of these conditions are vital to preventing vision loss and blindness, supporting the clinical rationale for CARA System’s development and adoption.

Forward-Looking Regulatory and Commercial Goals

The announcement includes forward-looking statements regarding regulatory marketing authorizations in Saudi Arabia and the U.S. DIAGNOS cautions that actual results may differ materially from these projections and disclaims any obligation to update forward-looking information based on new developments.

DIAGNOS’s international regulatory strategy, targeting approvals in Canada, Saudi Arabia, and the U.S., indicates these markets as priorities for expansion. Each jurisdiction requires distinct regulatory approaches while maintaining core product consistency.

Company Overview and Mission Alignment

DIAGNOS is a publicly traded Canadian company focused on early detection of critical eye health issues using artificial intelligence. The company aims to equip healthcare clinicians with enhanced diagnostic information to improve accuracy, streamline workflows, and boost patient outcomes globally. The recent regulatory approvals align with DIAGNOS’s mission of early disease detection through advanced diagnostics.

The immediate impact on DIAGNOS’s share price was not evident from public data. While Health Canada approval removes a regulatory barrier in Canada, it does not guarantee market adoption or revenue. Investors may monitor future announcements on commercial partnerships, deployment milestones, or financial guidance related to the CARA System.